ADBiotech Statistics

Total Valuation

ADBiotech has a market cap or net worth of KRW 23.13 billion. The enterprise value is 31.44 billion.

Market Cap	23.13B
Enterprise Value	31.44B

Important Dates

The next estimated earnings date is Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	n/a

Share Statistics

ADBiotech has 9.14 million shares outstanding. The number of shares has decreased by -9.99% in one year.

Current Share Class	n/a
Shares Outstanding	9.14M
Shares Change (YoY)	-9.99%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	47.07%
Owned by Institutions (%)	5.00%
Float	4.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.63
PB Ratio	5.23
P/TBV Ratio	9.90
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.71
EV / Sales	3.57
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-91.85

Financial Position

The company has a current ratio of 0.51, with a Debt / Equity ratio of 3.57.

Current Ratio	0.51
Quick Ratio	0.22
Debt / Equity	3.57
Debt / EBITDA	n/a
Debt / FCF	-33.34
Interest Coverage	-8.24

Financial Efficiency

Return on equity (ROE) is -122.00% and return on invested capital (ROIC) is -12.93%.

Return on Equity (ROE)	-122.00%
Return on Assets (ROA)	-10.70%
Return on Capital (ROIC)	-12.93%
Revenue Per Employee	149.14M
Profits Per Employee	-143.76M
Employee Count	59
Asset Turnover	0.34
Inventory Turnover	2.18

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.90% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-22.90%
50-Day Moving Average	2,919.30
200-Day Moving Average	3,055.00
Relative Strength Index (RSI)	43.66
Average Volume (20 Days)	76,582

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ADBiotech had revenue of KRW 8.80 billion and -8.48 billion in losses. Loss per share was -928.00.

Revenue	8.80B
Gross Profit	3.14B
Operating Income	-4.45B
Pretax Income	-11.23B
Net Income	-8.48B
EBITDA	-3.32B
EBIT	-4.45B
Loss Per Share	-928.00

Full Income Statement

Balance Sheet

The company has 1.87 billion in cash and 11.41 billion in debt, giving a net cash position of -9.54 billion or -1,044.04 per share.

Cash & Cash Equivalents	1.87B
Total Debt	11.41B
Net Cash	-9.54B
Net Cash Per Share	-1,044.04
Equity (Book Value)	3.20B
Book Value Per Share	483.95
Working Capital	-6.66B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -157.50 million and capital expenditures -184.83 million, giving a free cash flow of -342.33 million.

Operating Cash Flow	-157.50M
Capital Expenditures	-184.83M
Free Cash Flow	-342.33M
FCF Per Share	-37.45

Full Cash Flow Statement

Margins

Gross margin is 35.69%, with operating and profit margins of -50.58% and -96.39%.

Gross Margin	35.69%
Operating Margin	-50.58%
Pretax Margin	-127.66%
Profit Margin	-96.39%
EBITDA Margin	-37.74%
EBIT Margin	-50.58%
FCF Margin	n/a

Dividends & Yields

ADBiotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	9.99%
Shareholder Yield	9.99%
Earnings Yield	-36.68%
FCF Yield	-1.48%

Stock Splits

The last stock split was on May 26, 2021. It was a forward split with a ratio of 3.

Last Split Date	May 26, 2021
Split Type	Forward
Split Ratio	3

Scores

ADBiotech has an Altman Z-Score of -1.22. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.22
Piotroski F-Score	n/a